The KAT13A/SRC1 antibody targets the KAT13A protein, also known as Steroid Receptor Coactivator-1 (SRC-1), a member of the NCOA (nuclear receptor coactivator) family. SRC-1 was first identified as a transcriptional coactivator that enhances ligand-dependent activation of nuclear hormone receptors, including estrogen, progesterone, and thyroid hormone receptors. It functions by recruiting histone acetyltransferases (HATs) like p300/CBP and members of the ACAT family to modify chromatin structure, facilitating transcriptional activation. KAT13A/SRC1 is critical in regulating gene expression linked to metabolism, development, and hormone-responsive pathways.
Antibodies against KAT13A/SRC1 are widely used in research to study its role in transcriptional regulation, epigenetic modifications, and disease mechanisms. For example, SRC-1 overexpression has been implicated in hormone-dependent cancers (e.g., breast and prostate cancer) and metabolic disorders. These antibodies enable detection of protein expression, localization (e.g., nuclear vs. cytoplasmic shifts), and interaction partners via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. Structural studies using these antibodies have also clarified its modular domains, including bHLH-PAS, receptor interaction motifs, and HAT-binding regions. As a key player in the ACAT/HAT complex, SRC-1 remains a focus for understanding crosstalk between signaling pathways and chromatin remodeling, with therapeutic implications for targeting coactivators in disease.